Non-metastatic muscle-invasive bladder cancer: the role of age in receiving treatment with curative intent

被引:5
|
作者
van Hoogstraten, Lisa M. C. [1 ,2 ]
Witjes, J. Alfred [3 ]
Meijer, Richard P. [4 ]
Ripping, Theodora M. [1 ]
Kiemeney, Lambertus A. [2 ,3 ]
Aben, Katja K. H. [1 ,2 ]
机构
[1] Netherlands Comprehens Canc Org, POB 1281, NL-6501 BG Utrecht, Netherlands
[2] Radboud Univ Nijmegen Med Ctr, Radboud Inst Hlth Sci, Nijmegen, Netherlands
[3] Radboud Univ Nijmegen Med Ctr, Dept Urol, Nijmegen, Netherlands
[4] Univ Med Ctr Utrecht, Dept Oncol Urol, Utrecht, Netherlands
关键词
muscle-invasive bladder cancer (MIBC); patient and tumour characteristics; survival; treatment; urothelial bladder carcinoma; variation in healthcare; #BladderCancer; #blcsm; LONG-TERM OUTCOMES; RADICAL CYSTECTOMY; MODALITY THERAPY; PRESERVATION; CHEMOTHERAPY; PATTERNS; SCORE;
D O I
10.1111/bju.15697
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Objectives To evaluate which patient and tumour characteristics are associated with remaining untreated in patients with potentially curable, non-metastatic muscle-invasive bladder cancer (MIBC), and to compare survival of untreated vs treated patients with similar characteristics. Patients and methods For this cohort study, 15 047 patients diagnosed with cT2-T4aN0/xM0/x urothelial MIBC between 2005 and 2019 were identified in the Netherlands Cancer Registry. Factors associated with remaining untreated were identified using logistic regression analyses. Interhospital variation was assessed using multilevel analysis. Using a propensity score, the median overall survival (mOS) of untreated and treated patients was evaluated. Analyses were stratified by age (<75 vs >= 75 years). Results One-third of patients aged >= 75 years remained untreated; increasing age, worse performance status, worse renal function, cT4a stage and previous radiotherapy in the abdomen/pelvic area increased the odds of remaining untreated. One in 10 patients aged <75 years remained untreated; significant associations were only found for performance status, renal function and cT4a stage. Interhospital variation for remaining untreated was largest for patients aged >= 75 years, ranging from 37% to 69% (case-mix-adjusted). Irrespective of age, mOS was significantly worse for untreated patients: 6.4 months (95% confidence interval [CI] 5.1-7.3) vs 16.0 months (95% CI 13.5-19.1) for treated patients. Conclusion On average, one in five patients with non-metastatic MIBC remained untreated. Untreated patients were generally older and had a more unfavourable prognostic profile. Untreated patients had significantly worse overall survival, regardless of age. Age alone should therefore not affect treatment decision-making. Considering the large interhospital variation, a proportion of untreated patients might be wrongfully denied life-prolonging treatment.
引用
收藏
页码:764 / 775
页数:12
相关论文
共 50 条
  • [21] Treatment of muscle-invasive and advanced bladder cancer in 2020
    Patel, Vaibhav G.
    Oh, William K.
    Galsky, Matthew D.
    CA-A CANCER JOURNAL FOR CLINICIANS, 2020, 70 (05) : 404 - 423
  • [22] The role of surveillance in the treatment of patients with muscle-invasive bladder cancer after chemotherapy
    Hellenthal, Nicholas J.
    Ramirez, Michelle L.
    Evans, Christopher P.
    White, Ralph W. deVere
    BJU INTERNATIONAL, 2010, 105 (04) : 485 - 488
  • [23] The role of biomarkers in bladder preservation management of muscle-invasive bladder cancer
    Mitin, Timur
    Choudhury, Ananya
    WORLD JOURNAL OF UROLOGY, 2019, 37 (09) : 1767 - 1772
  • [24] Primary versus secondary muscle-invasive bladder cancer: survival after curative treatment
    Moller, Christina Tanem
    Fossa, Sophie D.
    Tafjord, Gunnar
    Babigumira, Ronnie
    Berge, Viktor
    Andreassen, Bettina Kulle
    SCANDINAVIAN JOURNAL OF UROLOGY, 2022, 56 (03) : 214 - 220
  • [25] Updates for the radiologist in non-muscle-invasive, muscle-invasive, and metastatic bladder cancer
    Jooae Choe
    Marta Braschi-Amirfarzan
    Sree Harsha Tirumani
    Atul B. Shinagare
    Kyung Won Kim
    Nikhil H. Ramaiya
    Katherine M. Krajewski
    Abdominal Radiology, 2017, 42 : 2710 - 2724
  • [26] Factors associated with utilization of neoadjuvant chemotherapy in charlson comorbidity zero non-metastatic muscle-invasive bladder cancer patients
    Au, Daniel
    Lee, Eugene K.
    Popoola, Taiye O.
    Parker, William P.
    Saint Onge, Jarron M.
    Ellis, Shellie D.
    INTERNATIONAL BRAZ J UROL, 2021, 47 (04): : 803 - 818
  • [27] Neoadjuvant Immunotherapy for Muscle-Invasive Bladder Cancer
    Peyrottes, Arthur
    Ouzaid, Idir
    Califano, Gianluigi
    Hermieu, Jean-Francois
    Xylinas, Evanguelos
    MEDICINA-LITHUANIA, 2021, 57 (08):
  • [28] Bladder conservation for muscle-invasive bladder cancer
    Hoskin, Peter
    Dubash, Suraiya
    EXPERT REVIEW OF ANTICANCER THERAPY, 2012, 12 (08) : 1015 - 1020
  • [29] Bladder-Sparing Treatment of Nonmetastatic Muscle-Invasive Bladder Cancer
    Ericson, Kyle J.
    Murthy, Prithvi B.
    Bryk, Darren J.
    Ramkumar, Rathika R.
    Broughman, James R.
    Khanna, Abhinav
    Mian, Omar Y.
    Campbell, Steven C.
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2019, 17 (12) : 697 - 707
  • [30] Updated 2016 EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer
    Witjes, J. Alfred
    Lebret, Thierry
    Comperat, Eva M.
    Cowan, Nigel C.
    De Santis, Maria
    Bruins, Harman Maxim
    Hernandez, Virginia
    Espinos, Estefania Linares
    Dunn, James
    Rouanne, Mathieu
    Neuzillet, Yann
    Veskimae, Erik
    van der Heijden, Antoine G.
    Gakis, Georgios
    Ribal, Maria J.
    EUROPEAN UROLOGY, 2017, 71 (03) : 462 - 475